Dasatinib monohydrate

CAS 863127-77-9

About the API

Systematic name N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
Trade name(s) Sprycel
Molecular Formula C22H26ClN7O2S •H2O
Molecular Weight 506.02082 g/mol
Physical properties Crystalline
Therapeutic category Antineoplastic & Immunomodul
Available formulations Oral Solid
Regulations Other Flag Other US DMF Flag US DMF

General Information

Dasatinib monohydrate is a kinase inhibitor indicated for the treatment of ‘ newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase ‘ adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib ‘ adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

 

Dasatinib was approved by the FDA in 2006 under the trade name Sprycel, for use as a second-line drug. It was approved in 2010 for use in newly diagnosed adults in the chronic phase. Dasatinib is synthesized through a chemical process involving carbon-nitrogen bond formation as major step.